(Q36376405)

13 August 2017

1 reference

title

The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome (English)

1 reference

13 August 2017

Jose M Nieto

1

1 reference

13 August 2017

Joseph R Pisegna

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

7

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

169-175

1 reference

Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Gastric secretion of acid and pepsin in patients with esophageal stricture and appropriate controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Management of the Zollinger-Ellison syndrome in pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Rabeprazole: an update of its use in acid-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Up-regulation of H2 receptor and adenylate cyclase in rabbit parietal cells during prolonged treatment with H2-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Omeprazole, its isomers, and the carcinoid question

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

Novel effects other than antisecretory action and off-label use of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.169

21 January 2018

Identifiers

DOI

10.1517/14656566.7.2.169

1 reference

13 August 2017

1 reference